A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

2025-524334-26-01 · tracked via the Priya Life Science EU tracker

Sponsor

Bristol-Myers Squibb Services Unlimited Company

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

26/02/2026

Enrollment target

Sites

Denmark

Condition studied

Endometrial cancer (EC), Advanced or metastatic breast cancer, Gastroesophageal cancer (GEC), Advanced or metastatic solid tumors, Platinum-resistant ovarian cancer (PROC), High grade serous ovarian cancer (HGSOC)

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524334-26-01 on CTIS ↗ ← All trials in the EU